JP2020513033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513033A5 JP2020513033A5 JP2020502549A JP2020502549A JP2020513033A5 JP 2020513033 A5 JP2020513033 A5 JP 2020513033A5 JP 2020502549 A JP2020502549 A JP 2020502549A JP 2020502549 A JP2020502549 A JP 2020502549A JP 2020513033 A5 JP2020513033 A5 JP 2020513033A5
- Authority
- JP
- Japan
- Prior art keywords
- activator
- mineral
- antagonist
- preparation according
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 103
- 239000011707 mineral Substances 0.000 claims description 103
- 239000012190 activator Substances 0.000 claims description 73
- 239000005557 antagonist Substances 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 40
- 239000011248 coating agent Substances 0.000 claims description 32
- 238000000576 coating method Methods 0.000 claims description 32
- 238000009472 formulation Methods 0.000 claims description 32
- 239000011859 microparticle Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 16
- 102000000589 Interleukin-1 Human genes 0.000 claims description 13
- 108010002352 Interleukin-1 Proteins 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 5
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 claims description 5
- 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 claims description 5
- 102100026015 Interleukin-1 family member 10 Human genes 0.000 claims description 5
- 108050004799 Interleukin-1 family member 10 Proteins 0.000 claims description 5
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 5
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 5
- 102100033500 Interleukin-33 Human genes 0.000 claims description 5
- 102100033474 Interleukin-36 alpha Human genes 0.000 claims description 5
- 108050004801 Interleukin-36 alpha Proteins 0.000 claims description 5
- 102100033503 Interleukin-36 gamma Human genes 0.000 claims description 5
- 101710195086 Interleukin-36 gamma Proteins 0.000 claims description 5
- 102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 claims description 5
- 101710089409 Interleukin-36 receptor antagonist protein Proteins 0.000 claims description 5
- 102100033502 Interleukin-37 Human genes 0.000 claims description 5
- 229960002964 adalimumab Drugs 0.000 claims description 5
- 229960004238 anakinra Drugs 0.000 claims description 5
- 239000000919 ceramic Substances 0.000 claims description 5
- 229960000403 etanercept Drugs 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 229960000598 infliximab Drugs 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 150000002739 metals Chemical class 0.000 claims description 5
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 102100033498 Interleukin-36 beta Human genes 0.000 claims description 2
- 108050003379 Interleukin-36 beta Proteins 0.000 claims description 2
- 229910052789 astatine Inorganic materials 0.000 claims description 2
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- 239000011247 coating layer Substances 0.000 description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480710P | 2017-04-03 | 2017-04-03 | |
| US62/480,710 | 2017-04-03 | ||
| PCT/US2018/025913 WO2018187344A1 (en) | 2017-04-03 | 2018-04-03 | Mineral coated microparticles for sustained delivery of biologically active molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513033A JP2020513033A (ja) | 2020-04-30 |
| JP2020513033A5 true JP2020513033A5 (enExample) | 2021-05-13 |
| JP7170031B2 JP7170031B2 (ja) | 2022-11-11 |
Family
ID=63712804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502549A Active JP7170031B2 (ja) | 2017-04-03 | 2018-04-03 | 生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12465654B2 (enExample) |
| EP (1) | EP3606512A4 (enExample) |
| JP (1) | JP7170031B2 (enExample) |
| KR (1) | KR20190130643A (enExample) |
| CN (1) | CN110691588A (enExample) |
| AU (1) | AU2018249816B2 (enExample) |
| BR (1) | BR112019020373A2 (enExample) |
| CA (1) | CA3058802A1 (enExample) |
| IL (1) | IL269607A (enExample) |
| WO (1) | WO2018187344A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3606512A4 (en) | 2017-04-03 | 2021-01-13 | Wisconsin Alumni Research Foundation | MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES |
| WO2022051247A1 (en) * | 2020-09-01 | 2022-03-10 | Dianomi Therapeutics, Inc. | Methods for treating or preventing inflammatory events |
| DE102020129648A1 (de) * | 2020-11-10 | 2022-05-12 | Leopold MTX GmbH | Pharmazeutische zusammensetzung |
| CN114917364A (zh) * | 2022-05-12 | 2022-08-19 | 云南大学附属医院 | 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法 |
| WO2024102801A2 (en) * | 2022-11-09 | 2024-05-16 | Wisconsin Alumni Research Foundation | Mineral-coated iron oxide microparticles and use of same including use for immunomodulation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| JP2003212756A (ja) * | 2002-01-21 | 2003-07-30 | Olympus Optical Co Ltd | 薬剤徐放剤 |
| CA2568352C (en) * | 2004-06-04 | 2011-09-13 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| US7655758B2 (en) * | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| AU2006290870B2 (en) * | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| JPWO2008041704A1 (ja) | 2006-10-02 | 2010-02-04 | 独立行政法人物質・材料研究機構 | 徐放性製剤 |
| US20100143439A1 (en) * | 2007-04-16 | 2010-06-10 | University Of Toledo | Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor |
| US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| US20090111763A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable polymeric particles for bone augmentation and methods of preparing and using the same |
| CN105688276A (zh) | 2008-02-29 | 2016-06-22 | 史密夫和内修有限公司 | 用于生物医学应用的梯度涂层 |
| US20100015049A1 (en) * | 2008-07-16 | 2010-01-21 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| JP2012503673A (ja) * | 2008-09-25 | 2012-02-09 | ティッシュ リジェネレーション システムズ インコーポレイテッド | ミネラルコーティングされたマイクロスフェア |
| US20160017368A1 (en) | 2013-02-19 | 2016-01-21 | Wisconsin Alumni Research Foundation | Inorganic coatings for the enhancement of chemical transfection |
| WO2016141242A1 (en) | 2015-03-03 | 2016-09-09 | Tissue Regeneration Systems, Inc. | Coating scaffolds |
| US10780054B2 (en) | 2015-04-17 | 2020-09-22 | Curevac Real Estate Gmbh | Lyophilization of RNA |
| EP3606512A4 (en) | 2017-04-03 | 2021-01-13 | Wisconsin Alumni Research Foundation | MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES |
| JP2020526515A (ja) | 2017-07-05 | 2020-08-31 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子 |
| US11628227B2 (en) | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
| EP3556728A1 (en) | 2018-04-16 | 2019-10-23 | Croda Denmark A/S | Organically modified mineral micro-particles, methods of preparing the same and uses thereof |
| US20190358344A1 (en) | 2018-05-23 | 2019-11-28 | Dianomi Therapeutics, Inc. | Mineral coated microparticles for sustained delivery of steroids |
| WO2023086816A1 (en) | 2021-11-09 | 2023-05-19 | Wisconsin Alumni Research Foundation | Mineral-coated substrates for stabilization of rna-based therapeutic compositions |
-
2018
- 2018-04-03 EP EP18780858.9A patent/EP3606512A4/en active Pending
- 2018-04-03 AU AU2018249816A patent/AU2018249816B2/en active Active
- 2018-04-03 BR BR112019020373-7A patent/BR112019020373A2/pt active Search and Examination
- 2018-04-03 KR KR1020197032235A patent/KR20190130643A/ko not_active Ceased
- 2018-04-03 JP JP2020502549A patent/JP7170031B2/ja active Active
- 2018-04-03 US US16/500,017 patent/US12465654B2/en active Active
- 2018-04-03 CA CA3058802A patent/CA3058802A1/en active Pending
- 2018-04-03 WO PCT/US2018/025913 patent/WO2018187344A1/en not_active Ceased
- 2018-04-03 CN CN201880036493.0A patent/CN110691588A/zh active Pending
-
2019
- 2019-09-24 IL IL26960719A patent/IL269607A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513033A5 (enExample) | ||
| JP7198310B2 (ja) | 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤 | |
| JP2017529382A5 (enExample) | ||
| JP2018505169A5 (enExample) | ||
| HUP0402230A2 (hu) | Többszörös bevonattal ellátott gyógyszer dózisforma | |
| CA2757019C (en) | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide | |
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| WO2019213686A1 (en) | Therapeutic compositions and uses therefor | |
| JP2019512003A (ja) | コパンリシブバイオマーカー | |
| Rhoades et al. | RETRACTED: Potential role of lampalizumab for treatment of geographic atrophy | |
| US12465654B2 (en) | Mineral coated microparticles for sustained delivery of biologically active molecules | |
| WO2023114984A1 (en) | Tead inhibitors and uses thereof | |
| JP2017031209A (ja) | アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
| JP2014529606A5 (enExample) | ||
| KR20130092617A (ko) | 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법 | |
| CN110461329A (zh) | 治疗血癌的PPARγ激动剂 | |
| US20200171022A1 (en) | Flt3 inhibitors for improving pain treatments by opioids | |
| JP2022527499A (ja) | Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 | |
| Clements et al. | Addition of Mineral‐Coated Microparticles to Soluble Interleukin‐1 Receptor Antagonist Injected Subcutaneously Improves and Extends Systemic Interleukin‐1 Inhibition | |
| CA2724982A1 (en) | Histamine binding protein | |
| CN117018202A (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
| Levin et al. | IL-17 and Other New Agents | |
| Sivanandy et al. | Comparison of efficacy and safety of newer drugs approved for the treatment of migraine disorder: A review | |
| CN1859901A (zh) | 含有加速作用开始的乙酰水杨酸的口服抗抑郁制剂 | |
| TW202508573A (zh) | 用於治療癌症之組合療法 |